<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0009308'>Adenocarcinoma</z:mp> of the esophagus and the gastroesophageal junction is the twentieth most common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> in the United States </plain></SENT>
<SENT sid="1" pm="."><plain>In developed countries, the incidence of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> is increasing 5% to 10% per year </plain></SENT>
<SENT sid="2" pm="."><plain>Despite the use of endoscopy for earlier detection, mortality from esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> has not declined </plain></SENT>
<SENT sid="3" pm="."><plain>Using an evidence-based approach, we review screening methods for esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, including the use of a symptom questionnaire, identification of patients with a family history of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, peroral or transnasal endoscopy, <z:chebi fb="8" ids="32594,32595">barium</z:chebi> swallow, fecal occult blood testing, and brush and balloon cytology </plain></SENT>
<SENT sid="4" pm="."><plain>Screening has not been shown to reduce rate of progression of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> to <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Many treatment options for dysplastic <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> or early <z:mp ids='MP_0002038'>carcinoma</z:mp> appear effective, but long-term follow-up data are not available </plain></SENT>
<SENT sid="6" pm="."><plain>There is currently insufficient evidence supporting population-based screening for <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Several risk factors, including severe reflux symptoms, male sex, and <z:hpo ids='HP_0001513'>obesity</z:hpo>, may identify patients with <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> who are at the greatest risk of the development of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>